> Details

Makhlin, Igor; Salinas, Ryan D; Zhang, Daniel; Jacob, Fadi; Ming, Gou-li; Song, Hongjun; Saxena, Deeksha; Dorsey, Jay F; Nasrallah, MacLean P; Morrissette, Jennifer JD; Binder, Zev A; O'Rourke, Donald M; Desai, Arati S; Brem, Steven; Bagley, Stephen J

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
  • Contributor: Makhlin, Igor; Salinas, Ryan D; Zhang, Daniel; Jacob, Fadi; Ming, Gou-li; Song, Hongjun; Saxena, Deeksha; Dorsey, Jay F; Nasrallah, MacLean P; Morrissette, Jennifer JD; Binder, Zev A; O'Rourke, Donald M; Desai, Arati S; Brem, Steven; Bagley, Stephen J
  • imprint: Future Medicine Ltd, 2019
  • Published in: CNS Oncology
  • Language: English
  • DOI: 10.2217/cns-2019-0014
  • ISSN: 2045-0907; 2045-0915
  • Keywords: General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p> Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a dismal prognosis. The EGFR gene is among the most commonly deranged genes in GBM and thus an important therapeutic target. We report the case of a young female with heavily pretreated EGFR-mutated GBM, for whom we initiated osimertinib, an oral, third-generation tyrosine kinase inhibitor that irreversibly inhibits EGFR and has significant brain penetration. We then review some of the main challenges in targeting EGFR, including lack of central nervous system penetration with most tyrosine kinase inhibitors, molecular heterogeneity of GBM and the need for enhanced specificity for the EGFR mutations relevant in GBM. </jats:p>
  • Access State: Open Access